Jeff Ajer - Nektar Therapeutics Independent Director
| NKTR Stock | USD 1.32 0.06 4.35% |
Director
Mr. Jeff Robert Ajer is an Independent Director of the Company. Mr. Ajer currently serves as Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical Inc., a global biotechnology company that develops and commercializes innovative therapies for people with serious and lifethreatening rare disorders. From October 2012 to January 2014, Mr. Ajer served as Senior Vice President and Chief Commercial Officer of BioMarin. From April 2009 to October 2012, Mr. Ajer served as BioMarins Vice President, Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Prior to joining BioMarin, Mr. Ajer served in various roles at Genzyme Corporation beginning in November 2003, most recently as Vice President, Global Transplant Operations from December 2004 to August 2005. Mr. Ajers experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer also served on the board of directors of True North Therapeutics since 2017.
| Age | 55 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
| Phone | 415 482 5300 |
| Web | https://www.nektar.com |
Nektar Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1095) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/28/2024, Return On Tangible Assets is likely to grow to -0.66. In addition to that, Return On Capital Employed is likely to grow to -0.38. At this time, Nektar Therapeutics' Total Assets are relatively stable compared to the past year. As of 04/28/2024, Non Currrent Assets Other is likely to grow to about 8.3 M, while Other Assets are likely to drop slightly above 2.5 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Susan Sholtis | PetIQ Inc | 51 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| James Clarke | PetIQ Inc | 45 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
| Larry Bird | PetIQ Inc | 63 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
| Will Santana | PetIQ Inc | 45 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Scott Huff | PetIQ Inc | 46 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Gary Michael | PetIQ Inc | 77 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
Management Performance
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.15 |
Nektar Therapeutics Leadership Team
Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer | ||
| Mark Wilson, Chief Sec | ||
| Lutz Lingnau, Independent Director | ||
| Roy Whitfield, Independent Director | ||
| Scott Greer, Independent Director | ||
| Mary Tagliaferri, Senior Vice President - Clinical Development and Chief Medical Officer | ||
| Christopher Kuebler, Independent Director | ||
| Karin Eastham, Independent Director | ||
| Jeff Ajer, Independent Director | ||
| Maninder Hora, Senior Vice President - Pharmaceutical Development and Manufacturing Operations | ||
| Brian MD, Chief Officer | ||
| Robert Chess, Independent Chairman of the Board | ||
| Wei Lin, Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs | ||
| Dennis Winger, Independent Director | ||
| Vivian Wu, Director Affairs | ||
| Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs | ||
| Sandra Gardiner, Interim Officer | ||
| Kevin Brodbeck, VP Operations | ||
| Joseph Krivulka, Independent Director | ||
| Gilbert Labrucherie, Senior Vice President General Counsel, Secretary | ||
| John Nicholson, CFO and Sr. VP | ||
| Stephen Doberstein, Chief Scientific Officer and Sr. VP | ||
| Howard Robin, CEO and President and Director | ||
| Ivan Gergel, Senior Vice President - Drug Development & Chief Medical Officer | ||
| MD LAc, Chief Officer | ||
| John Northcott, Strategic Advisor | ||
| Loui Madakamutil, VP Research | ||
| Robert Bacci, Senior Operations | ||
| Susan Wang, Independent Director | ||
| Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin. |
Nektar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.15 | ||||
| Operating Margin | (1.28) % | ||||
| Current Valuation | 169.16 M | ||||
| Shares Outstanding | 183.62 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 66.76 % | ||||
| Number Of Shares Shorted | 3.11 M | ||||
| Price To Earning | 8.02 X | ||||
| Price To Book | 2.34 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Nektar Stock analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.474 | Quarterly Revenue Growth 0.085 | Return On Assets (0.15) | Return On Equity (1.11) |
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.